Quarterly ResultAug 6, 2026, 06:02 AM
LifeStance Q2 Revenue +26% to $435.4M; Raises FY26 Guidance
AI Summary
LifeStance Health Group reported strong second-quarter 2026 financial results, with revenue increasing 26% year-over-year to $435.4 million and achieving a net income of $23.6 million, a significant improvement from a net loss in the prior year. Adjusted EBITDA surged 94% to $66.0 million. The company also raised its full-year 2026 revenue and Adjusted EBITDA guidance, reflecting continued growth and operational efficiency. Additionally, LifeStance announced a new $100 million share repurchase program.
Key Highlights
- Q2 2026 revenue increased 26% to $435.4 million.
- Q2 2026 net income was $23.6 million, compared to a net loss of $3.8 million in Q2 2025.
- Q2 2026 Adjusted EBITDA grew 94% to $66.0 million.
- Clinician base increased 11% to 8,542, with 193 net new clinicians in Q2.
- Full-year 2026 revenue guidance raised to $1.685 billion to $1.725 billion.
- Full-year 2026 Adjusted EBITDA guidance raised to $215 million to $235 million.
- Board approved a new $100 million share repurchase program.
Price Impact
More from LFST